Boehringer Ingelheim selects the Ennov platform for Regulatory Information Management

February 8, 2019

headquarters ingelheim rim ennovFollowing a comprehensive review of the Regulatory Information Management marketplace, Boehringer Ingelheim have chosen the Ennov platform for their global RIM needs across both human and veterinary sectors.

The Ennov platform was the #1 choice for user experience and coverage of business architecture. Additionally, Ennov demonstrated genuineness in its interactions and rated highly in areas such as company vision and roadmap.

Olivier Paris, CEO Ennov welcomes the new partnership saying “We are proud to have the opportunity to work with Boehringer Ingelheim on this important initiative and look forward to a successful long term relationship with such a highly respected company.

Boehringer Ingelheim join Ennov’s ever increasing list of strategic life sciences customers who together drive the evolution of what has become one the industry’s leading unified regulatory information management platforms.

About Ennov

Headquartered in Paris, France and with offices in the UK and US, Ennov has been developing innovative, powerful and easy-to-use software for document and process management for over twenty years.

Using the knowledge and best practices gained from more than 150 Life Sciences customers and over 500 total customers, Ennov has designed and built solutions specifically for the health and life sciences sectors for Quality, Pharmacovigilance, Clinical Operations and Regulatory Affairs.

More information about Ennov can be found on

About Boehringer Ingelheim

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

More information about Boehringer Ingelheim can be found on

Share :


Register for free to access to our library of exclusive content!

Highlight Post

Recent Posts